Literature DB >> 21847622

Repeat treatment for recurrent hepatocellular carcinoma: is it validated?

Yoji Kishi1, Akio Saiura, Junji Yamamoto, Rintaro Koga, Makoto Seki, Ryo Morimura, Ryuji Yoshioka, Norihiro Kokudo, Toshiharu Yamaguchi.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) usually recurs repeatedly and locoregional treatment is attempted unless liver function has deteriorated. This study was aimed to evaluate the effect of repeated treatment on patient prognosis.
METHODS: The HCC recurrence pattern and types of treatment for recurrence after hepatic resection were reviewed in 134 patients. The effects of repeated treatment on prognosis were evaluated. Univariate and multivariate analyses were performed to determine the prognostic predictors after initial recurrence.
RESULTS: Median number of treatments after recurrence was 3 (range, 0-12). Transarterial chemoembolization was the most common treatment. The number of treatments, but not the type of treatment, was associated with the prognosis. Multivariate analysis showed that a >20% indocyanine green retention rate at 15 min (hazard ratio [HR] = 2.65; 95% confidential interval [CI], 1.53-5.62), size of primary tumor >5 cm (HR = 1.81; 95% CI, 1.05-3.08), recurrence-free interval <1 year (HR = 2.17; 95% CI, 1.28-3.81), size of recurrent tumor >3 cm (HR = 2.61; 95% CI, 1.03-5.77-0.95), and extrahepatic recurrence (HR = 6.35; 95% CI, 3.49-11.39) were independent predictors of poor survival.
CONCLUSION: The prognosis after recurrence is poor in cases with large tumors or poor liver function. Repeated locoregional treatment contributes to prolong patient prognosis, especially in cases with a small tumor size, long recurrence-free interval, and no extrahepatic metastases.

Entities:  

Mesh:

Year:  2011        PMID: 21847622     DOI: 10.1007/s00423-011-0837-0

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  30 in total

1.  Radiofrequency ablation of recurrent hepatocellular carcinoma after hepatectomy: therapeutic efficacy on early- and late-phase recurrence.

Authors:  Wei Yang; Min Hua Chen; Shan Shan Yin; Kun Yan; Wen Gao; Yan Bin Wang; Ling Huo; Xiao Peng Zhang; Bao Cai Xing
Journal:  AJR Am J Roentgenol       Date:  2006-05       Impact factor: 3.959

2.  The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma.

Authors:  Hong-Yan Cheng; Xiang Wang; Dong Chen; Ai-Min Xu; Yu-Chen Jia
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

3.  Repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  Toshiyuki Itamoto; Hideki Nakahara; Hironobu Amano; Toshihiko Kohashi; Hideki Ohdan; Hirotaka Tashiro; Toshimasa Asahara
Journal:  Surgery       Date:  2007-05       Impact factor: 3.982

4.  Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response.

Authors:  O Ernst; G Sergent; D Mizrahi; O Delemazure; J C Paris; C L'Herminé
Journal:  AJR Am J Roentgenol       Date:  1999-01       Impact factor: 3.959

5.  Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old.

Authors:  Kojiro Taura; Iwao Ikai; Etsuro Hatano; Hideaki Fujii; Naoki Uyama; Yasuyuki Shimahara
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

6.  Repeat hepatectomy is the most useful treatment for recurrent hepatocellular carcinoma.

Authors:  K Sugimachi; S Maehara; S Tanaka; M Shimada; K Sugimachi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

7.  A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.

Authors:  Chong Zhong; Rong-ping Guo; Jin-qing Li; Ming Shi; Wei Wei; Min-shan Chen; Ya-qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-01       Impact factor: 4.553

8.  Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma.

Authors:  Gi-Hong Choi; Dong-Hyun Kim; Chang-Moo Kang; Kyung-Sik Kim; Jin-Sub Choi; Woo-Jung Lee; Byong-Ro Kim
Journal:  Ann Surg Oncol       Date:  2007-11-15       Impact factor: 5.344

9.  Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma.

Authors:  R Izumi; K Shimizu; T Iyobe; T Ii; M Yagi; O Matsui; A Nonomura; I Miyazaki
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

10.  Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study.

Authors:  Y Kawano; A Sasaki; S Kai; Y Endo; K Iwaki; H Uchida; K Shibata; M Ohta; S Kitano
Journal:  Eur J Surg Oncol       Date:  2008-03-05       Impact factor: 4.424

View more
  9 in total

1.  Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection.

Authors:  Tsuyoshi Notake; Akira Kobayashi; Hiroji Shinkawa; Takuya Kawahara; Akira Shimizu; Takahide Yokoyama; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Matsuyama; Masatoshi Makuuchi; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2017-03-16       Impact factor: 3.402

Review 2.  Current management of hepatocellular carcinoma.

Authors:  Parissa Tabrizian; Sasan Roayaie; Myron E Schwartz
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 3.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

4.  Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma.

Authors:  Wei-Ju Huang; Yung-Ming Jeng; Hong-Shiee Lai; Fang-Yu Bonnie Sheu; Po-Lin Lai; Ray-Hwang Yuan
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

5.  Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.

Authors:  Peng S Koh; Albert C Y Chan; Tan T Cheung; Kenneth S H Chok; Wing C Dai; Ronnie T P Poon; Chung M Lo
Journal:  HPB (Oxford)       Date:  2016-01       Impact factor: 3.647

6.  Impact of surgery on quality of life in patients with hepatocellular carcinoma.

Authors:  Yoshihiro Mise; Shouichi Satou; Takeaki Ishizawa; Junichi Kaneko; Taku Aoki; Kiyoshi Hasegawa; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

7.  Surgery strategy of 13 cases to control bleeding from the liver on laparoscopic repeat liver resection for recurrent hepatocellular carcinoma.

Authors:  Shuiping Yu; Tang Bo; Binzong Hou; Jiangfa Li; Xueling Zhou
Journal:  J Minim Access Surg       Date:  2019 Jul-Sep       Impact factor: 1.407

8.  Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation.

Authors:  Liang-He Lu; Jie Mei; Anna Kan; Yi-Hong Ling; Shao-Hua Li; Wei Wei; Min-Shan Chen; Yong-Fa Zhang; Rong-Ping Guo
Journal:  Cancer Med       Date:  2020-02-28       Impact factor: 4.452

9.  Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma.

Authors:  Michinori Matsumoto; Katsuhiko Yanaga; Hiroaki Shiba; Shigeki Wakiyama; Taro Sakamoto; Yasuro Futagawa; Takeshi Gocho; Yuichi Ishida; Toru Ikegami
Journal:  Ann Gastroenterol Surg       Date:  2021-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.